Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells

Molecular Biology of the Cell

Volumn 16, Issue 8, 2005, Pages 3488-3500

  Im, Eunok ^a   Venkatakrishnan, Annapurna ^a   Kazlauskas, Andrius ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; COMPLEMENTARY DNA; ENDOSTATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LYSOSOME ENZYME; MESSENGER RNA; PROTEINASE; RETROVIRUS VECTOR; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATTLE; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SILENCING; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTION; WESTERN BLOTTING;

ANIMALS; CASPASES; CATHEPSIN B; CATTLE; CELLS, CULTURED; ENDOSTATINS; ENDOTHELIAL CELLS; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; MICROSCOPY, ELECTRON; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEASE INHIBITORS; RETINA; RNA INTERFERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23044432584     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E04-11-1029     Document Type: Article

References (58)

1. Ahmed, N. K., Martin, L. A., Watts, L. M., Palmer, J., Thomburg, L., Prior, J., and Esser, R. E. (1992). Peptidyl fluoromethyl ketones as inhibitors of cathepsin B. Implication for treatment of rheumatoid arthritis. Biochem. Pharmacol. 44, 1201-1207.
2. Aiello, L. P. et al. (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1519-1520.
3. Aronson, N. N., Jr., and Barrett, A. J. (1978). The specificity of cathepsin B. Hydrolysis of glucagon at the C-terminus by a peptidyldipeptidase mechanism. Biochem. J. 171, 759-765.
4. Balaji, K. N., Schaschke, N., Machleidt, W., Catalfamo, M., and Henkart, P. A. (2002). Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J. Exp. Med. 196, 493-503.
5. Barrett, A. J., and Kirschke, H. (1981). Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol. 80 (Pt C), 535-561.
6. Bergers, G. et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744.
7. Buck, M. R., Karustis, D. G., Day, N. A., Honn, K. V., and Sloane, B. F. (1992). Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J. 282, 273-278.
8. Cai, J., Ahmad, S., Jiang, W. G., Huang, J., Kontos, C. D., Boulton, M., and Ahmed, A. (2003). Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 52, 2959-2968.
9. Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
10. Dawson, D. W., Pearce, S. F., Zhong, R., Silverstein, R. L., Frazier, W. A., and Bouck, N. P. (1997). CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707-717.
11. Ebert, D. H., Deussing, J., Peters, C., and Dermody, T. S. (2002). Cathepsin L. and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J. Biol. Chem. 277, 24609-24617.
12. Esser, R. E., Watts, L. M., Angelo, R. A., Thornburg, L. P., Prior, J. J., and Palmer, J. T. (1993). The effects of fluoromethyl ketone inhibitors of cathepsin B on adjuvant induced arthritis. J. Rheumatol. 20, 1176-1183.
13. Felbor, U., Dreier, L., Bryant, R. A., Ploegh, H. L., Olsen, B. R., and Mothes, W. (2000). Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 19, 1187-1194.
14. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., and Moore, M. W. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442.
15. Ferrara, N., and Davis-Smyth, T. (1997). The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25.
16. Ferrara, N., Gerber, H. P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
17. Ferreras, M., Felbor, U., Lenhard, T., Olsen, B. R., and Delaisse, J. (2000). Generation and degradation of human endostarin proteins by various proteinases. FEBS Lett. 486, 247-251.
18. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
19. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L., (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16, 4604-4613.
20. Fukai, N. et al. (2002). Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J. 21, 1535-1544.
21. Gitlin, J. D., and D'Amore, P. A. (1983). Culture of retinal capillary cells using selective growth media. Microvasc. Res. 26, 74-80.
22. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., and Bouck, N. P. (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87, 6624-6628.
23. Guicciardi, M. E., Deussing, J., Miyoshi, H., Bronk, S. F., Svingen, P. A., Peters, C., Kaufmann, S. H., and Gores, G. (2000). Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J. Clin. Invest. 106, 1127-1137.
24. Halangk, W., Lerch, M. M., Brandt-Nedelev, B., Roth, W., Ruthenbuerger, M., Reinheckel, T., Domschke, W., Lippert, H., Peters, C., and Deussing, J. (2000). Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J. Clin. Invest. 106, 773-781.
25. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
26. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., and Neckers, L. M. (2002). Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277, 29936-29944.
27. Jaakkola, P. et al. (2001). Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by deregulated prolyl hydroxylation. Science 292, 468-472.
28. Joyce, J. A., Baruch, A., Chehade, K., Meyer-Morse, N., Giraudo, E., Tsai, F. Y., Greenbaum, D. C., Hager, J. H., Bogyo, M., and Hanahan, D. (2004). Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453.
29. Keppler, D., Sameni, M., Moin, K., Mikkelsen, T., Diglio, C. A., and Sloane, B. F. (1996). Tumor progression and angiogenesis: cathepsin B & Co. Biochem. Cell Biol. 74, 799-810.
30. Knott, R. M., Robertson, M., Muckersie, E., Folefac, V. A., Fairhurst, F. E., Wileman, S. M., and Forrester, J. V. (1999). A model system for the study of human retinal angiogenesis: activation of monocytes and endothelial cells and the association with the expression of the monocarboxylate transporter type 1 (MCT-1). Diabetologia 42, 870-877.
31. Kobayashi, H., Schmitt, M., Goretzki, L., Chucholowski, N., Calvete, J., Kramer, M., Gunzler, W. A., Janicke, F., and Graeff, H. (1991). Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J. Biol. Chem. 266, 5147-5152.
32. Kruszewski, W. J., Rzepko, R., Wojtacki, J., Skokowski, J., Kopacz, A., Jaskiewicz, K., and Drucis, K. (2004). Overexpression of cathepsin B correlates with angiogenesis in colon adenocarcinoma. Neoplasma 51, 38-43.
33. Kuo, C. J. et al. (2001). Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. J. Cell Biol. 152, 1233-1246.
34. Linebaugh, B. E., Sameni, M., Day, N. A., Sloane, B. F., and Keppler, D. (1999). Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur. J. Biochem. 264, 100-109.
35. Mackay, E. A. et al. (1997). A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease. Eur. J. Biochem. 244, 414-425.
36. Mai, J., Sameni, M., Mikkelsen, T., and Sloane, B. F. (2002). Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol. Chem. 383, 1407-1413.
37. Maxwell, P. H. (2004). HIF-1's relationship to oxygen: simple yet sophisticated. Cell Cycle 3, 156-159.
38. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J, (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
39. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
40. Ortega, N., Jonca, F., Vincent, S., Favard, C., Ruchoux, M. M., and Plouet, J. (1997). Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am. J. Pathol. 151, 1215-1224.
41. Ory, D. S., Neugeboren, B. A., and Mulligan, R. C. (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93, 11400-11406.
42. Ottino, P., Finley, J., Rojo, E., Ottlecz, A., Lambrou, G. N., Bazan, H. E., and Bazan, N. G. (2004). Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity. Mol. Vis. 10, 341-350.
43. Plate, K. H., Breier, G., Weich, H. A., and Risau, W. (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848.
44. Qian, F., Bajkowski, A. S., Steiner, D. F., Chan, S. J., and Frankfater, A. (1989). Expression of five cathepsins in murine melanomas of varying metastatic potential and normal tissues. Cancer Res. 49, 4870-4875.
45. Rasnick, D. (1985). Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B. Anal Biochem. 149, 461-465.
46. Riccio, M., Di Giaimo, R., Pianetti, S., Palmieri, P. P., Melli, M., and Santi, S. (2001). Nuclear localization of cystatin B, the cathepsin inhibitor implicated in myoclonus epilepsy (EPM1). Exp. Cell Res. 262, 84-94.
47. Rodriguez-Manzaneque, J. C., Lane, T. F., Ortega, M. A., Hynes, R. O., Lawler, J., and Iruela-Arispe, M. L. (2001). Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteiriase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 38, 12485-12490.
48. Schotte, P., Schauvliege, R., Janssens, S., and Beyaert, R. (2001). The cathepsin B inhibitor z-FA.fmk inhibits cytokine production in macrophages stimulated by lipopolysaccharide. J. Biol. Chem. 276, 21153-21157.
49. Schotte, P. et al. (1998). Cathepsin B-mediated activation of the proinflammatory caspase-11. Biochem. Biophys. Res. Commun. 252, 379-387.
50. Semenza, G. L. (2000). HIF-1 and human disease: one highly involved factor. Genes Dev. 24, 1983-1991.
51. Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y., Forrester, W. C., and Shi, Y. (2002). A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99, 5515-5520.
52. Takahashi, T., Dehdarani, A. H., Yonezawa, S., and Tang, J. (1986). Porcine spleen cathepsin B is an exopeptidase. J. Biol. Chem. 261, 9375-9381.
53. Turk, B., Turk, D., and Turk, V. (2000). Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 1477, 98-111.
54. Valius, M., Bazenet, C., and Kazlauskas, A. (1993). Tyrosines 1021 and 1009 are phosphorylation sites in the carboxy terminus of the platelet-derived growth factor receptor beta subunit and are required for binding of phospholipase C gamma and a 64-kilodalton protein, respectively. Mol. Cell Biol. 13, 133-143.
55. Watnick, R. S., Cheng, Y. N., Rangarajan, A., Ince, T. A., and Weinberg, R. A. (2003). Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3, 219-231.
56. Wen, W., Moses, M.A., Wiederschain, D., Arbiser, J. L., and Folkman, J. (1999). The generation of endostatin is mediated by elastase. Cancer Res. 59, 6052-6056.
57. Wolters, P. J., and Chapman, H. A. (2000). Importance of lysosomal cysteine proteases in lung disease. Respir. Res. 1, 170-177.
58. Yanamandra, N., Gumidyala, K. V., Waldron, K. G., Gujrati, M., Olivero, W. C., Dinh, D. H., Rao, J. S., and Mohanam, S. (2004). Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 23, 2224-2230.